Senate bill seeks to curb US reliance on China in drug industry

US lawmakers are intensifying their strategic competition with China by targeting the healthcare sector. Bipartisan senators have unveiled new legislation designed to curb American reliance on China for pharmaceuticals and biotechnology.

The proposed bill seeks to increase transparency surrounding foreign influence in the drug industry. This move comes amid growing concerns about the United States' dependence on China for critical drug ingredients and the broader medical supply chain. Washington's strategic rivalry with Beijing has increasingly encompassed healthcare, extending beyond previous focuses on semiconductors and artificial intelligence.

The legislation aims to bolster domestic capabilities and reduce vulnerabilities in the pharmaceutical sector. By scrutinizing Chinese investment, senators hope to secure the US drug supply and enhance national security. The move signals a broader trend of decoupling in critical industries, with lawmakers prioritizing domestic production and supply chain resilience.